IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Treatment Agnostic Analysis of the HAWK and HARRIER Studies.
Humans
Animals
Angiogenesis Inhibitors
/ therapeutic use
Hawks
Visual Acuity
Intravitreal Injections
Tomography, Optical Coherence
Receptors, Vascular Endothelial Growth Factor
/ therapeutic use
Birds
Macular Degeneration
/ drug therapy
Recombinant Fusion Proteins
/ therapeutic use
Wet Macular Degeneration
/ diagnosis
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
medline:
30
3
2023
pubmed:
28
1
2023
entrez:
27
1
2023
Statut:
ppublish
Résumé
To assess the effect of the total number of fluid-free months after loading on visual and anatomical outcomes in neovascular age-related macular degeneration patients receiving anti-vascular endothelial growth factor therapy. This post hoc analysis pooled patient-level data from the brolucizumab 6 mg (n = 718) and aflibercept 2 mg (n = 715) arms of the HAWK and HARRIER randomized clinical trials. Based on data from Weeks 12 to 96, patients were assigned to one of five categories based on fluid-free visits (FFVs; the total number of monthly visits at which they were observed to be without retinal fluid). Three definitions of "fluid-free" were explored based on the location of the fluid observed. Patients allocated to Categories 4 (15-21 FFV) and 5 (22 FFV, always dry) consistently had the best visual and anatomical outcomes at Week 96, whereas patients allocated to Categories 1 (0 FFV, never dry) and 2 (1-7 FFV) consistently had the worst visual and anatomical outcomes. Variability in retinal thickness over time was lowest in Categories 4 and 5. Absence of retinal fluid at more visits after loading has a positive association with visual and anatomic outcomes in neovascular age-related macular degeneration patients, regardless of fluid type.
Identifiants
pubmed: 36705252
doi: 10.1097/IAE.0000000000003699
pii: 00006982-202304000-00014
pmc: PMC10035657
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Recombinant Fusion Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
632-640Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.
Références
Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014;98:1144–1167.
CATT Research Group, Martin DF, Maguire MG, Ying G-s, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–1908.
Mones J, Singh RP, Bandello F, et al. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica 2020;243:1–8.
Dervenis N, Younis S. Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration. Clin Ophthalmol 2016;10:1117–1122.
Lee H, Jo A, Kim HC. Three-dimensional analysis of morphologic changes and visual outcomes in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2017;58:1337–1345.
Ying GS, Kim BJ, Maguire MG, et al. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 2014;132:915–921.
Sagiv O, Zloto O, Moroz I, Moisseiev J. Different clinical courses on long-term follow-up of age-related macular degeneration patients treated with intravitreal anti-vascular endothelial growth factor injections. Ophthalmologica 2017;238:217–225.
Chatziralli I, Nicholson L, Vrizidou E, et al. Predictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly aflibercept. Ophthalmology 2016;123:1762–1770.
Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;120:1860–1870.
Jaffe GJ, Ying GS, Toth CA, et al. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology 2019;126:252–260.
Sharma S, Toth CA, Daniel E, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology 2016;123:865–875.
Wickremasinghe SS, Sandhu SS, Busija L, et al. Predictors of AMD treatment response. Ophthalmology 2012;119:2413–2414.e5.
Kodjikian L, Decullier E, Souied EH, et al. Predictors of one-year visual outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. Retina 2018;38:1492–1499.
Segal O, Barayev E, Nemet AY, et al. Prognostic value of hyperreflective foci in neovascular age-related macular degeneration treated with bevacizumab. Retina 2016;36:2175–2182.
Wickremasinghe SS, Janakan V, Sandhu SS, et al. Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol. Retina 2016;36:1331–1339.
Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 2016;50:1–24.
Waldstein SM, Simader C, Staurenghi G, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology 2016;123:1521–1529.
Holekamp NM, Sadda S, Sarraf D, et al. Effect of residual retinal fluid on visual function in ranibizumab-treated neovascular age-related macular degeneration: effect of retinal fluid on vision outcomes in HARBOR. Am J Ophthalmol 2022;233:8–17.
Guymer RH, Markey CM, McAllister IL, et al. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology 2019;126:723–734.
Jaffe GJ, Kaiser PK, Thompson D, et al. Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology 2016;123:1856–1864.
Schmidt-Erfurth U, Mulyukov Z, Gerendas BS, et al. Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis. Eye (Lond) 2022; doi: 10.1038/s41433-022-02077-4. Online ahead of print.
doi: 10.1038/s41433-022-02077-4
Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 2021;128:89–99.
Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 2020;127:72–84.
Jhaveri C, Dugel P, Wykoff CC, et al. Visual and anatomical outcomes for brolucizumab and aflibercept in patients with nAMD: 96-week data from HAWK and HARRIER. Data Presented at the ASRS Annual Meeting. Chicago, USA. July 26‒30, 2019.
Evans RN, Reeves BC, Maguire MG, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol 2020;138:1043–1051.